189 related articles for article (PubMed ID: 28413963)
1. Overview of Cantharidin and its Analogues.
Wang G; Dong J; Deng L
Curr Med Chem; 2018; 25(17):2034-2044. PubMed ID: 28413963
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues.
Sakoff JA; Ackland SP; Baldwin ML; Keane MA; McCluskey A
Invest New Drugs; 2002 Feb; 20(1):1-11. PubMed ID: 12003183
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells.
Yeh CB; Su CJ; Hwang JM; Chou MC
Eur J Med Chem; 2010 Sep; 45(9):3981-5. PubMed ID: 20691337
[TBL] [Abstract][Full Text] [Related]
4. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines.
McCluskey A; Ackland SP; Bowyer MC; Baldwin ML; Garner J; Walkom CC; Sakoff JA
Bioorg Chem; 2003 Feb; 31(1):68-79. PubMed ID: 12697169
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.
Hsieh FS; Hung MH; Wang CY; Chen YL; Hsiao YJ; Tsai MH; Li JR; Chen LJ; Shih CT; Chao TI; Chen KF
Lung Cancer; 2017 Oct; 112():81-89. PubMed ID: 29191605
[TBL] [Abstract][Full Text] [Related]
6. Anhydride modified cantharidin analogues. Is ring opening important in the inhibition of protein phosphatase 2A?
McCuskey A; Keane MA; Mudgee LM; Sim AT; Sakoff J; Quinn RJ
Eur J Med Chem; 2000 Oct; 35(10):957-64. PubMed ID: 11121622
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A.
Shan HB; Cai YC; Liu Y; Zeng WN; Chen HX; Fan BT; Liu XH; Xu ZL; Wang B; Xian LJ
Anticancer Drugs; 2006 Sep; 17(8):905-11. PubMed ID: 16940800
[TBL] [Abstract][Full Text] [Related]
8. Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
Hill TA; Stewart SG; Sauer B; Gilbert J; Ackland SP; Sakoff JA; McCluskey A
Bioorg Med Chem Lett; 2007 Jun; 17(12):3392-7. PubMed ID: 17451951
[TBL] [Abstract][Full Text] [Related]
9. Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
McCluskey A; Bowyer MC; Collins E; Sim ATR ; Sakoff JA; Baldwin ML
Bioorg Med Chem Lett; 2000 Aug; 10(15):1687-90. PubMed ID: 10937725
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
Thaqi A; Scott JL; Gilbert J; Sakoff JA; McCluskey A
Eur J Med Chem; 2010 May; 45(5):1717-23. PubMed ID: 20153915
[TBL] [Abstract][Full Text] [Related]
11. Norcantharidin analogues: synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition.
Hill TA; Stewart SG; Gordon CP; Ackland SP; Gilbert J; Sauer B; Sakoff JA; McCluskey A
ChemMedChem; 2008 Dec; 3(12):1878-92. PubMed ID: 19025735
[TBL] [Abstract][Full Text] [Related]
12. Cantharidin use among pediatric dermatologists in the treatment of molluscum contagiosum.
Coloe J; Morrell DS
Pediatr Dermatol; 2009; 26(4):405-8. PubMed ID: 19689514
[TBL] [Abstract][Full Text] [Related]
13. Exploiting protein phosphatase inhibitors based on cantharidin analogues for cancer drug discovery.
Deng L; Dong J; Wang W
Mini Rev Med Chem; 2013 Jun; 13(8):1166-76. PubMed ID: 23373656
[TBL] [Abstract][Full Text] [Related]
14. Cantharidin as an antitumor agent: a retrospective review.
Deng LP; Dong J; Cai H; Wang W
Curr Med Chem; 2013; 20(2):159-66. PubMed ID: 23210849
[TBL] [Abstract][Full Text] [Related]
15. The effects of cantharidin and cantharidin derivates on tumour cells.
Liu D; Chen Z
Anticancer Agents Med Chem; 2009 May; 9(4):392-6. PubMed ID: 19442040
[TBL] [Abstract][Full Text] [Related]
16. Cantharidin-based small molecules as potential therapeutic agents.
Puerto Galvis CE; Vargas Méndez LY; Kouznetsov VV
Chem Biol Drug Des; 2013 Nov; 82(5):477-99. PubMed ID: 23809227
[TBL] [Abstract][Full Text] [Related]
17. Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.
McCluskey A; Walkom C; Bowyer MC; Ackland SP; Gardiner E; Sakoff JA
Bioorg Med Chem Lett; 2001 Nov; 11(22):2941-6. PubMed ID: 11677131
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitization of tumour cells by cantharidin and some analogues.
Price WA; Stobbe CC; Park SJ; Chapman JD
Int J Radiat Biol; 2004 Apr; 80(4):269-79. PubMed ID: 15204704
[TBL] [Abstract][Full Text] [Related]
19. The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
McCluskey A; Ackland SP; Gardiner E; Walkom CC; Sakoff JA
Anticancer Drug Des; 2001 Dec; 16(6):291-303. PubMed ID: 12375882
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics of cantharidin in tumor cells.
Kadioglu O; Kermani NS; Kelter G; Schumacher U; Fiebig HH; Greten HJ; Efferth T
Biochem Pharmacol; 2014 Feb; 87(3):399-409. PubMed ID: 24231507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
